• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    1524747 Polypeptides IMPERIAL CHEMICAL INDUSTRIES Ltd 21 April 1977 [11 May 1976] 19327/76 Heading C3H [Also in Division C2] A polypeptide of the Formula (I) H-Pyroglu- His - Trp - Ser - Tyr - A - B - Arg - Pro - E - F wherein (i) A is D-Tyr, D-Tyr(Me), D-Ser,(But), D-Phe, D-Ala or D-Trp; B is Leu or MeLeu; E is Azgly; F is NH2; (ii) A is Azgly or Azala; B is Leu; E is a direct bond; F is NHEt; and the pharmaceutically-acceptable and veterinarily-acceptable acid addition salts thereof. Peptides (I) prepared are Peptide intermediates isolated are: DECAPEPTIDE: H - Pyroglu - His - Trp - Ser- Tyr(But) - D - Phe - MeLeu - Arg(H<+>) - Pro- Azgly-NH2. OCTAPEPTIDES: Z and H - Trp Ser - Tyr- D - Ala - Leu- Arg(H<+>) - Pro - Azgly - NH2. HEPTAPEPTIDES: Z and H - Trp - Ser- Tyr(Bzl) - Azgly - Leu - Arg(H<+>) Pro - NHEt; Z and H - Trp - Ser - Tyr(Bzl) Azala - Leu- Arg(H<+>) - Pro - NHEt. HEXAPEPTIDES: Z - Tyr(Bzl) D - Ala - Leu- Arg(N02) - Pro - Azgly NH2; H - Tyr D - Ala- Leu - Arg(H<+>) - Pro - Azgly - NH2; Z - Tyr(Bzl)- D Phe - Leu - Arg(NO2) - Pro - Azgly NH2; H Tyr D Phe - Leu - Arg(H<+>) - Pro Azgly- NH2; Z - Tyr(Bzl) D - Trp - Leu - Arg(NO2)- Pro - Azgly - NH2- H - Tyr - D - Trp - Leu- Arg(H<+>) - Pro - Azgly - NH2; Z - Tyr(Bzl) - DTyr(Me) - Leu - Arg(NO2) - Pro - Azgly - NH2; H - Tyr - D - Tyr(Me) Leu - Arg(H<+>) Pro- Azgly - NH2; Z - Tyr(Bzl) D - Ser(But) - Leu- Arg(N02) - Pro - Azgly - NH2; H - Tyr - DSer(But) Leu - Arg(H<+>) - Pro - Azgly - NH2; Z - Tyr(Bzl) - D - Tyr(Me) - MeLeu - Arg(NO2)- Pro - Azgly - NH2; H Tyr - D - Tyr(Me)- MeLeu - Arg(H+) - Pro Azgly - NH2; Z - Tyr(But) - D - Phe - MeLeu - Arg(NO2) - Pro- Azgly - NH2; H - Tyr(But) D - Phe - MeLeu- Arg(H<+>) - Pro - Azgly - NH2. PENTAPEPTIDES: Z - Tyr(Bzl) - Azgly - Leu- Arg(NO2) - Pro - NHEt; H - Tyr(Bzl) - Azgly- Leu - Arg(H<+>) - Pro - NHEt; Z - Tyr(Bzl)- Azala - Leu - Arg(NO2) - Pro - NHEt; H - Tyr- (Bzl) - Azala Leu - Arg(H<+>) - Pro - NHEt. TETRAPEPTIDES: Z - Leu - Arg(NO2) - Pro- Azgly - NH2; H - Leu - Arg(H<+>) Pro - Azgly- NH2; H - Pyroglu His - Trp - Ser - OMe, NHNH2 and N3. TRIPEPTIDES: Z - Tyr(Bzl) Azgly - Leu- OMe, NHNH2 and N3; Z - Tyr(Bzl) - Azala- Leu OMe and OH; Z - Tyr(Bzl) - D - Phe- Leu - OMe, NHNH2 and N3 ; Boc and HArg(NO2) - Pro Azgly - NH2; Z - Tyr(Bzl)- D - Trp - Leu - OMe,NHNH2 and N3; ZTyr(Bzl)-D-Tyr(Me) -Leu-OMe, NHNH2 and N3; Z-Tyr(Bzl) - D - Ser(But) - Leu - OMe, NHNH2 and N3; Z - Tyr(Bzl) D - Tyr(Me) - MeLeu- OMe, NHNH2 and N3; Z - Tyr(But) - D - Phe - MeLeu - OMe, NHNH2 and N3. DIPEPTIDES: Boc and H - Arg(NO2) Pro- NHEt; H - Pyroglu His - OMe, NHNH2 and N3; Z and H - Pro - Azgly - NH2; Z - Leu- Arg(NO2) - OH; Z - Tyr(Bzl) - D - Ala - OMe, NHNH2 and N3 ; Z and H - D - Phe - Leu - OMe; H - Trp-Ser - OMe; Z and H - D - Tyr(Me)- Leu- OMe; Z and H - D - Trp - Leu - OMe ; Z and H - D - Ser(But) - Leu - OMe; Z and H - DTyr - MeLeu - OMe; Z and H D - Phe - MeLeu- OMe. A pharmaceutical composition or veterinary composition, which may be administered parenterally or orally, comprises peptide (I) in association with a pharmaceutically-acceptable or veterinarily acceptable diluent or carrier.
    公开号:SU910116A3
    申请号:SU772480485
    申请日:1977-05-11
    公开日:1982-02-28
    发明作者:Сваруп Дутта Ананд；Джон Альберт Фарр Баррингтон；Брайан Гайлз Майкл
    申请人:Империал Кемикал Индастриз Лимитед (Фирма)；
    IPC主号:
    专利说明:

    (5) METHOD FOR OBTAINING POLYPEPTIDES OR THEIR SALTS
    one
    The invention relates to a method for producing new polypeptides, compounds having biological activity that can be used in medicine.
    In peptide chemistry for the condensation of peptide fragments and amino residues
    Loiu-His-Trp-Ser-Tyr-A-B-Arg-Pro-E-P, where if A is D-Tyr, D-Tyr (Me); D.-Ser, D-Ser (); D-Phe; D-Ala; D-Trp, TO B - Leu, Meheu; E - Azgly; F - W2, or if A - Arg 1y, Arala, TO B - Leu; E is a simple bond; F - .-, or their salts, consisting in that peptide fragments are condensed
    lot widely use azide and carbodiimide methods lf.
    The purpose of the invention is to obtain new polypeptides with interesting biological properties.
    The goal is achieved by the method of obtaining polypeptides of the formula 20 25 LGlu-His-OH b1 and His-trp-Ser-OH, or their azides with peptides H-Thr-Zeg-Tug-A-B-Agd-Pro-E-E, or H-Tyr-AB-Arg-Pro-EF, respectively, the values of A, B, F and E are as indicated above, followed by isolation of the desired product as a base or salt. The purity of the product is monitored by chromatography on a thin layer C of those) silica gel (brand Kieselgel). For the appearance of chromatograms, solvent systems are used at the following volume ratios: butan-1-ol: acetic acid: water 4: 1: 5 (M, A); butan-1-ol: acetic acid: water: pyridine 15: 3: 12: 10 (Rf, B); butan-2-ol: 3 w / wt ammonium hydroxide 3: 1 (Rf, C); acetonitrile: water 3: 1 (Rf, D); acetone chloroform 1: 1 (Rf, E); chloroform: this nol 1: 4 (Rf, F); cyclohexane ethylace tat 1: 1 (Rf, G); cyclohexane: ethyl acetate: methanol 1: 1: 1 (Rf, H); chloroform: methanol: water 11: 8: 2 (Rf, K); chloroform: methanol 19: 1 (Rf, P) and chloroform: methanol 9: 1 (Rf, Q). In all cases, the plates are viewed in ultraviolet light and treated with such reagents as fluoresc 1min, ninhydrin and chlorine-starch-iodine. Acid hydrolysates are obtained to obtain an amino acid composition by heating peptides or protected peptides with 6N. hydrochloric acid containing 1 weight / vol. phenol in an evacuated and sealed ampoule for 1b h at 100 C. The amino acid composition of each hydrolyte is determined using an amino acid analyzer. The term was carried out in the usual manner used in the description of the examples, which means that after carrying out the reaction all the solid residue is filtered off, the filtrates are evaporated to dryness at a lower temperature, the residue in ethyl acetate is washed with 20% citric acid, water, saturated sodium bicarbonate and water dried over anhydrous sodium sulphate, then ethyl acetate is evaporated in vacuo, resulting in a final PSUF. The following abbreviations are used in the process description: OCP - 2,4,5-trichlorophenyl complex th ether; Br1 - benzyl; Z is benzyloxycarbonyl; BOS tert.-butoxycarbonyl; DMF - dimethylformamide. Examples 1 t8. Synthesis of L-pyroglutamyl-1-histidyl-1 tryptophyl-1-seryl-L-tyrosyl-L-1-leucyl-1-argyl-L-prolyl-E - F. General method m (table 1, examples 1-3). To a cooled (OS) suspension of L-pyroglutamyl-L-histidine hydrazide (0.2 mmol) in 0.9 ml of dimethylformamide and 0.7 ml of dimethyl sulfoxide were added with stirring 5.7 n solution of hydrogen chloride in dioxane (0.8 mmol). After 5 minutes of vigorous stirring, a pro-cancer solution is obtained. The solution is cooled to -20 ° C, 0.22 mmol, tert, butyl nitrite is added and stirring is continued for 25 minutes. Then the temperature is lowered to -30 ° C and the solution is neutralized by adding 0.8 mmol of triethylamine. After the introduction of the pre-cooled mixture (-20C) L-tryptophyl-1-seryl-1-tyrosyl-A-1-leucyl-L-arGINYL-L-prolyl-E-F-Dihydrochloride (0.1 mmol) obtained by hydrogenolysis of N -benzyloxycarbonyl derivative in 80 vol% aqueous methanol solution containing 2 equivalents of hydrogen chloride over 5% by weight palladium on carbon for 16 triethylamine (0.1 mmol) in 1 ml of dimethylformamide, the reaction mixture is stirred for 24 hours at. Dimethylformamide is distilled off in vacuo, and the residue is chromatographed on Sephadex 1H-20, using dimethylformamide as eluent. The resulting peptide hydrochloride is purified by separation chromatography on Sephadex &amp; 25 using n-butanol: acetic acid: water: pyridine 5: 1: 5: 1 as a solvent. Synthesis of 1-pyroglutamyl-1-histidyl-1-trypfyl- 1-Seryl-1-tyrosyl-A-B-L-arginyl-1-prolyl-azaglycine-amide of General Method VI (Table 17 examples 4-8). 1-pyroglutamyl-1-histidyl-1-tryptophyl-1-serine-hydrazine (0.2 mmol) is dissolved in 4 ml of dimethylformamide and converted to azide according to the method of p. It is condensed according to the method of chlorohydrate L-tyrolysyl-A- B-b-arginyl-1-prolyl azaglycine-amide (o, 15 mmol) obtained by catalytic reduction of L-benzyloxy-carbonyl-0-benzyl-1-tyrosyl-A-1-leucyl- (N-nitro) -1-arginyl- 1-prolyl-azaglycine-amide in 80 aqueous methanol for 20 hours over 5 wt.% Palladium on charcoal, the final product in the form of hydrochloride is purified as described above. The characteristics of the compounds, half-valued according to the proposed method cot-5, is fine for examples 1-8, are given in table 1. EXAMPLE 9 and 10. Compounds are prepared using one of the basic methods m or 6.. Characteristics of the compounds obtained are presented in table 2. FIG. 1 and 2 show schemes for the preparation of starting materials, method t; fig. is the same; method p. In the circles, numbers related to a particular stage are taken. I. A solution of 19.9+ g (80 mmol); -benzyloxycarbonyl-1-proline and 8.8 ml (80 mmol) of M-methylmorpholine in 200 ml of dry tetrahydrofuran are cooled to -20 ° C. 7.15 ml (76 mmgl) of ethyl chloroformate are added dropwise and after two minutes of stirring, 20 ml (ZOO mmol) pre-cooled to 70% aqueous solution of ethylamine and continue stirring for 18 h at C. Then the reaction mixture is treated in the usual way, the residue is recrystallized from a mixture of ethyl acetate; petroleum ether (k.p.60-8os). Exit 1.97 g (53.7 U. mp. 107-1084; Cc (3 | 55i 3.88 (s, 1 in methanol) Rfu 0, b9; Rf p 0.53; RfFO, 67;, b 2; R.fpO, 57; Rj M II.Catalytic reduction of the product was carried out over 5% by weight of palladium on carbon in aqueous ethanol containing one equivalent of hydrogen chloride for 5 hours at room temperature. 111. A solution of 13.5 g (2 , 3 mmol) M-tert.-butoxycarbonyl-M nitro-1 arginine, 7.15 g (7 mmol) of L-propyl-ethylamide hydrochloride, 11.5 g (86 mmol) of 1-hydroxybenzotriazole and 6758 ml (D7 mmol) of triethylamine in dimethylformamide, it is cooled to O C, and 9.13 g of C, mmoles of dicyclohexylcarbodiimide are added to it. The reaction mixture is stirred for a while, the precipitated precipitate is filtered off and the filtrate is evaporated to dryness in vacuo. The residue is partitioned into ethyl acetate and water in countercurrent (k transfer). The aqueous phases are combined, evaporated to dryness, and the residue is separated from the n-butanol and 5 vol. Aqueous acetic acid phases in countercurrent (12 niepeHOcoB). The crude peptide obtained by evaporation of the combined phases of n-6 166thanol was purified by column chromatography on silica gel using 5% v / v methanol in chloroform and 10% by volume methanol in chloroform as eluent. The fractions containing the product are combined and evaporated to dryness. The residue is dissolved in water and the solution is passed through a column with an anion exchange resin (AG 1-X2) to remove Threto-butoxycarbonyl-M nitroarginine. The column is washed with water, and the combined aqueous fractions and wash waters are dried at a lower temperature to obtain an azpeptide derivative , yield 16.67 g (89); m.p. 109-111 ° C (with decomposition); p ,, 0 (s, 1 in methanol); Rf, A 0.62; L, B 0, R., C 0,59; Rjf, D 0.70; Rr, E 0.20; Rr, F 0.60; R And 0.61; R K 0.85; Rj Q 0.13. IV. A solution of the N-tert.-butoxycarbonyl derivative in ethyl acetate is treated with a solution of Sn „HCl in ethyl acetate C equivalent) for 1 h at room temperature. V. (RsH). A solution of 2.90 g (22 mmol) of tert.-butoxycarbonylhydrazide and 11.71 g (20 mmol) of N-benzyloxycarbonyl-0-benzyl-1-tyrosine-2 ,, 5-trichlorophenyl ester in 0 ml of dimethylformamide is kept at room temperature during the night. After processing this product in accordance with the usual procedure and then recrystallizing the obtained residue from ether-petroleum ether (b.p. 60-80 ° C), protected hydrazine is obtained as a white powder, yield 3.6 g (67); mp.12b127 C; i; d3 | f-13, 2C (s, 1 to methanol; R, O 0.82; R, E 0.65; R $ F 0.63; Ri, H 0.70 VI Solution () of 5.19 g (10 mmol) of 1- (M-benzyloxycarbonyl-0-benzyl-1-tyrosyl) -2-tert.-butyloxycarbonyl hydrazide in 50 ml of ethyl acetate is treated with 5N hydrogen chloride in 8 ml (0 mmol) ethyl acetate for 1 h at room temperature. Ethyl acetate is evaporated in vacuo, the resulting hydrochloride is washed with ether and dried. VI. I. (). To 75 ml of a solution of the above hydrochloride in tetrahydrofuran is added 1.115 g (8 mmol) of triethylamine, then 1.3b g (8 mmol), methyl ester of N-carbonyl-L-leucine. eaktsionnuyu mixture was kept at room temperature for 16 hours, then it was treated in a usual manner, and the resulting residue perekrystallizovyvagot from a mixture of ethyl acetate. Petroleum ether b.p. 6080S) to give derivative azatripeptidnogo g, yield 11.1%, m.p. 15b-157C; Go L -10.3 (s, 1 in methanol); R O 0.81; Rr., E = 0.45; R, P 0.26; R., Q 0.47. . 5 ml (100 mmol) of hydrazine hydrate are added to 2.95 g (5 mmol of the solution of N-benzyloxycarbonyl-O-benzyl-C-tyro-zylazoglycyl-L-leucine methyl ester in 50 ml of methanol. The mixture is kept at room temperature for 2 hours. , then the hydrazide is precipitated with water and recrystallized from methanol: ether, yield 2.74 g (92.8%); mp. 1–9–170 ° C; (s, 1 in dimethylformamide D: n L P 7A D; l 7C CX G P 77. R |, A 0.76; Rp a 0.75; R;, C 0.73; Rr D 0.63; Rr F 0.60; Rr, H 0.55. IX. X. (RH ) 1.18 g (20 mmol of M-benzyloxycarbonyl-0-benzyl-1-tyrosyl zaglycyl-1-lingine hydrazide) were diluted with 10 ml of dimethylformamide and after cooling A solution of 1.46 ml (8 mmol-) of 5.49 M solution of hydrogen chloride in dioxane is added to the solution, then 0.25 ml (2.2 mmol) of tert-butyl nitrite is added to the reaction mass. After 5 min, the solution cooled before and added to it a pre-cooled mixture of 0.83 bg (2.2 mmol)) hydrochloride M-nitro-1-arginyl-1-proline-ethylic and 1.43 ml (10.2 mmol) of triethylamine in 10 ml dimethylformamide. The reaction mixture was stirred for 1 hour and for 48 hours. The reaction mixture was worked up in the usual way, the pentapeptide derivative was purified by chromatography on a column of silica gel using chloroform and 3 vol.-methanol in the elution solvent. chloroform, get 0.695 g (38,5); R ,. A 0.71; R ,, 8о, 7 R С 0.84. Xi (). Catalytic reduction of the product is carried out with 5% by weight palladium on carbon in 80 vol. -A aqueous solution of acetic acid containing two equivalents of hydrogen chloride. XM With vigorous stirring, to a cooled qo-20 ° C solution of 33.84 g (100 mmol) of N-benzyloxy 168 carbvinyl-and-tryptophan and 11.0 ml (100 mmol) of N-methylmorpholine in 200 ml of tetrahydrofuran, 9.0 ml ( 95 mmol) ethyl chloroformate. After 2 minutes, a pre-cooled (-20 ° C) solution of 17.10 g (11 O mmol) of methyl ester 1-ser.1na and 12.1 ml (110 mmol) of N-methylmorpholine in 150 ml is introduced into the reaction mass. dimethylformamide and continue to stir at -20 ° C for 30 minutes and then at room temperature for 3 hours. After treating the product obtained in the usual way, an oil is obtained. After two crystallizations from a mixture of ethyl acetate and petroleum ether (bp 60-80 C), a dipeptide derivative is obtained, yield 30.53 g (69.5); m.p. 140.5-141 C; , 13 ° (c 1.4 in dimethylformamide) XIII. To 1 l of solution in methanol VIII L 1 p i-h -.- g-, -, i-, .i - h sp of 30.53 g (69.5 mmol} of the ester prepared above, 15 ml of 62 w / v solution of hydrazine hydrate was added. After 16 h, the hydrazide was separated, washed with methanol, ether and recrystallized from hot ethanol; get 23, 18 g (75.8), mp 178-179C; CofJ 25, 27 (s, 1 in dimethylformamide); Rri, D 0.65; E 0.20; RJ F 0743; Rr, H 0.50 R c and, and; t g u, 4j); rvt., xiv, xv. 0.77 ML (4.64 MMOL 6.02 N. hydrogen chloride in dioxane is added with stirring to a cooled () solution of 0.502 g (D, 36 mmol) of N-benzyloxycarbonyl-1-tryptophyl-1 serine hydrazide in 5. ml of dimethylformamide , then 0.14 ml (1.22 mmol) of tert.-butyl nitrite is introduced into the reaction mixture. After 30 minutes, the solution is cooled to -30 ° C and neutralized by adding 0.65 ml of triethylamine. Pre-cooled (- 20 With a mixture of 0.547 g (0.77 mmol) 1-tyrosyl zaglycyl-and-leucyl-L-j-zrgynyl-L-proline ethylamide dichlorohydrate and 0.108 ml (, (., 11 mmol) of triethylamine in 5 ml of dimethylfo The reaction mixture was stirred for 1 h at and for 48 h at 4 ° C. Then filtered, the filtrate was evaporated to dryness in vacuo.The resulting crude peptide was purified on a chromatography column with silica gel using 10% chloroform as eluent. methanol in chloroform and a mixture of chloroform:. methanol: water 11: 8: 2,
    9
    yield 0, l42k g (52.9), 84 (s, 1, 5 in methanol); Rr ,, A 0.61; Rr, C 0.36; R |, D 0, б7Т Rr, К .0.90. XVIII. () The process is carried out under the conditions described in stage V ,. yield 66%; t, pl. 102-10it C, i: olJ 15.5 (s, 1 in methanol); R, O, 0.76 RJ, E, 0.68; R ±, F 0.76; R, H 0.7.
    XIX. (R-Me). Similar to stage VI.
    Xx. (Rsme). Analogous stage VII, output 93, so pl. I5-1 6C; ; ". , 7 (p. 1,2, in methanol); Rp, A 0.88; R, B 0.88; R {, C 0.83; , D 0.80; R, t 0.59; Rf, H 0.75.
    XXI.to to the grower 2, k g (mmol) of the methyl ester of N-benzyloxycarbonyl-0-benzyl-1-tyrosyl-azalinyl-1-leucine in 36 ml of methanol
    at room temperature, 12 ml (12 mmol) of 1N sodium hydroxide are added with stirring, stirring is continued for another 3 hours. Methanol is distilled off in vacuum, and kO ml of the aqueous residue is acidified with citric acid (pH 3), the product is extracted with ethyl acetate . After washing the 5-acetate extract with water and drying over sodium sulfate, the solvent is distilled off, the residue is dissolved in 200 ml of a mixture of dimethylformamide: water 3: 2 and injected into a column with 100 ml of resin AC 1 X-2. The column is washed with 50 ml of the solvent indicated above, and the tripeptide is eluted with 0.2 M acetic acid in a mixture of dimethylformamide: water 3: 2. The fractions containing the tripeptide are combined and evaporated in vacuo, the residue is triturated with EFROM) yield 1.22 g (51.7); m.p. 195С (with decomposition,, 4 (s, 1 in dimethylformamide).
    XXII. (). Similar to stage 28, yield) 25.9 (c., 1 in methanol); Rr. A, 0.72; Rr, B 0.76;
    Rr, 0.85.
    XXIll (). Similar to stage XI.
    Xxiv. (). It is similar to stage XV, with the difference that the final product is purified by filtration on Sephadex LH-20 gel in dimethylformamide, after chromatographic purification on
    silica gel; output 63 / s; jell-33 2.76 (with 0.8 in methanol); RJ, A 0.58; R, C 0.42; R, O 0.65; Rf, K 0.95.
    Xxv. K 2k; 3 g IOO mmol) stirred and cooled (O C) sus1610
    M-benzyloxycarbonyl-1-proline suspensions added 11.2 g (100 mmol) of semicarbazide hydrochloride and 5 ml (100 mmol) of triethylamine in 200 ml of dimethylformamide, 20.6 g (100 mmol) of dicyclohexylcarbodiimide and stirring continued for 16 h at k C. Dicyclohexyl urea is filtered off and the filtrate is concentrated. 200 ml of water are added to the residue and the product from the solution is treated with ethyl acetate (C3 x 50, il). After 1 h from the aqueous solution, the product precipitates. Recrystallization from
    aqueous methanol get dipeptide amide; yield 1b, 5 g SZZ.E); mp.189190 ° C; rotJ ii3, 6 ° (c, 1.4 in dimethylformamide); Rjg, D 0.5V, R, F 0.52; Rr. H 0.38; R, K 0.78.
    Xxvi. Catalytic reduction over 5 wt .- palladium on coal in 80 vol. -Aqueous dimethylformamide for 6 h at room temperature in the presence of two equivalents of hydrogen chloride.
    Xxvii. To a solution of 8.24 g (31 mmol) of M-benzyloxycarbonyl-1-leucine and 55 ml (32.5 mmol) of triethylamine in 100 ml of tetrahydrofuran, at a temperature of from -10 to -15 ° C, 2.83 ml (29 , 5 mmol of ethyl chloroformate. The reaction mixture is stirred at this temperature for 3 minutes and poured into a vigorously stirred solution of 5.79 g (31 mmol) of N nitro-1-arginine in 15.5 ml (31 mmol) of 2N sodium hydroxide and 50 ml dimethylformamide at -10 ° C. The resulting mixture was stirred at -10 ° C for 30 minutes and then at room temperature for 1 hour. The solvent was distilled off in vacuum, the residue was divided by 50 ml of ethyl acetate and 50 ml of water. The aqueous phase is separated, extracted with two portions of ethyl acetate. The combined organic phases are washed with 25 ml of water. The aqueous layers are separated, combined and acidified with a saturated solution of citric acid, the product extracted with ethyl acetate (3x100 ml). The ethyl acetate extracts are combined, washed with water, dried over sodium sulfate and evaporated to dryness. After recrystallization of the residue from ethyl acetate-petroleum ether (t &apos; kip. 60-80 ° C) get dipeptide, the output of 8.98 g (); m.p. 150-1b5 ° C (with decomposition). 1.1 XXVII. To the solution cooled to the standard 9.2. g (20 mmol) of N-benzyloxycarbonyl-1-leucyl- {N-nitro-L-arginine, 2 g (20 mmol) of L-prolyl azaglycine amide hydrochloride, 5, g (0 mmol) of 1-hydroxybenzo. triazole and 3 ml ( 20 mmol) of triethylamine in dimethylformamide was added 8.2 g (0 mmol) of dicyclohexylcarbodiimide. The reaction mixture was stirred overnight at room temperature. Dicyclohexyl urea is filtered, the filtrate is evaporated to dryness. After recrystallization of the residue from methanol: ether, the tetrapeptide derivative is obtained, yield 12.2 g (38.3); m.p. 88-90 ° C (Ld-30, 2 (p. 1.0 in dimethylformamide; R. F, D 0.57; Rjf, F 0, AO; Ri:, H 0.26; R |, K 0.63 XXIX. Hydrogenation over 5 wt.% Palladium on carbon in aqueous ethanol for 16 hours in the presence of two equivalents of hydrogen chloride. XXX.6, g (11.0 mmol) of N-benzyloxycarbonyl-0-benzyl-1-tyrosine-2 , k, 5-trichlorophenyl ester and 1.39b g (10 mmol) of D-alanine methyl ester hydrochloride are dissolved in 50 ml of dimethylformamide and 1, ml (10.0 mmol) of triethyl amine, and the solution is stirred overnight at room temperature. The reaction mixture is processed in the usual way, the residue is Installed from hot ethyl acetate, protected dipeptide methyl ester is obtained, yield 248 3.772 g (77.2%); mp. 1bЗ ° CjfriJr -12, (s, 1.1 in dimethylformamide). XXXI.A solution of 3.35 g (7.0 mmol) M-benzyloxycarbonyl-0-benzyl-1-tyrosyl-O-alanine methyl ester in ml of warm methanol is treated with 10 ml (120 mmol) of 62 w / v hydrazine hydrate, the mixture is left overnight at . The hydrazide precipitated in the precipitate is filtered off, washed with methanol and ether and recrystallized twice from boiling methanol. Yield “3.068 g (89.22;); m.p. 217 C; olj | 3 -20.4 (s, i; i in dimethylformamide) F, A 0.73; Rr, B 0.75; R. C, 0.67; R Ri, D 0.70; R, E 0.50; R, F 0, R |, H 0.67; R., K 0.85; R, Q 0.25. XXXII and XXXIII. While stirring, to a cooled () solution of 612 1, 1 8-g (2, mmol) of N-bendyloxycarbonyl-O-benzyl-L-tyrosyl-O-alanine hydrazide was added 1.6 ml of C 9.6 mmol) 6.02 M solution of hydrogen chloride in dioxane, then 0.29 ml (2.52 lonti) tert.-butyl nitrite. After 15 minutes, a pre-cooled (-20 ° C) solution of 1.03 g (2.0 mmol) of 1-leucyl-1-arginyl-1-prolyl azaglycine-amide dihydrochloride and 1.62 ml (11.6 mmol) of triethylamine in 15 ml of dimethylformamide. The resulting mixture is stirred for 2 hours. At room temperature, triethylamine hydrochloride is filtered off and the filtrate is evaporated to dryness in vacuo. The residue is placed on a silica gel column, the product is eluted with 5% by volume of methanol in chloroform, 10% by volume of methanol, in chloroform and a mixture of chloroform: methanol: water 11: 8: 2. The fractions containing the product were combined, and the peptide was re-purified by silica gel column chromatography, using an acetonitrile: water 3: 1 mixture as eluting solvent. Yield 890 mg (46.4%); Cot3 | f-45, (s, 1.1 in methanol); RP, A 0, R, B 0.69; K, C 0, Ai: XXXIV. Similar to stage XI. XXXV. Similar to stage XV, yield, t (c, 1.3 in methanol); Rf, A 0.80; R., 0.7%; Rr, D 0.65; Rf, K 0.95. XXXVIII; Similar in stage III / A 0.9; OUTPUT 69, m.p. 135 С; R, O, 0.64; Rf., 8 0.65; Kg., C. O. Ro, pH g - l Tf- -l. ". R |, F 0.35; R |, H 0.19 R, k 0.86. XXXIX-. Similar to stage IV. XL. (A 0 - Phe). A solution of 7.2 g (2.8 mmol) of N-benzyloxycarbonyl-Dphenylalanine and 3, b 2 g of 25 mmol of L-leucine methyl ester in 100 ml of ethyl acetate is cooled before it is added 5.15 g (25 mmol) of dicyclohexycarbodiimide. The reaction mixture is stirred at with overnight. After the usual treatment, followed by recrystallization of the residue from ethyl acetate: petroleum ether (mp. 60-80 s), the dipeptide is 9.1 g (86%); m.p. 123-124 0 &amp; iJl) -8. (s, 2.1 in methanol); Rr, D 0.76; Rj, E 0, b5; Rr, F 0, Rj, H 0.73. XL I. (A D - Phe). Catalytic reduction over 5 wt .- palladium on carbon P. ethanol, containing 3 one equivalent of hydrogen chloride, for 5 m. XL II. (A D-Phe). To a saturated solution, E8 g (8.36 mmol) of N-benzyloxy-carbonyl-O-benzyl-L-tyrosine-2, 4,5-trichlorophenyl ester and 2.5 g (7.6 mmol) of hydrochloride 0- 1.1 ml of the phenylalanil-1-leucine methyl ester ester in dimethylformamide (7.6 mmol triethyls is continued and stirring is continued overnight at room temperature. The triethylamine hydrochloride is filtered off and the filtrate is evaporated to dryness. After recrystallization of the residue from aqueous methanol, the tripeptide derivative is obtained with the release of 3.6 g, (69,); mp. ISS-IS C; Rr, D 0.82 Rp, E 0.69; Ro, H 0.78; R., R 0.71 R, Q 0.82. XLII. (A D-Phe). A solution of 3, g (5.0 mmol) of the methyl ester described in stage XL II and hydrazine hydrate (60 mmol) in 30 ml of dimethylformamide is stirred at room temperature for k hours and concentrated to a small volume, the hydrazide is precipitated by adding 500 ml of water, filtered, washed with water, methanol: ether I: and ether and dried (Yield 2.9 (85.91); mp 179-180 ° C; RP, A 0.81 Rr, B 0.79; Cg Rj, E 0.49; Ri, F 0.65; R., H 0.67; D P P 9C. R. P P: P; 7 RJ, P 0.25; R, Q 0,: 57. XL IV and XLV. (). 1.83 ml (11 mmol) of a solution of 6.02 M of hydrogen chloride in dioxane is added to a solution of 1.86 g (2.75 mmol) of N-benzyl-oxobarbonyl-0-benzyl-L-tyrosyl-D-phenylsilane-L-leucine hydrazide in 5 ml at -20 ° C, 0.33 ml (2.89 mmol) of tert-butyl nitrite was introduced into the mixture. After 2 minutes, -1.89 ml (13.5 mmol) of a pre-cooled solution () of triethylamine and 1.02 g (2.5 mmol) of N -nitro-b-argninyl-b-prolyl-zaglycine-amide hydrochloride in 10 ml are added. dimethylformamide, the reaction mixture is stirred overnight at C. A hexapeptide derivative is obtained, which is purified by column chromatography on silica gel (20 g) using 5% by volume methanol in chloroform, 10% by volume methanol in chloroform as eluting solvents and a mixture of chloroform: methanol: water 11: 8: 2, vy614 SOD product 0.7t g (29.3), t.ml. 13 / 139С; Rf, A 0.68; Rr, B 0.72; RP, C 0.58; Rr, D U, S2; Rr, H 0.39: R :, to 0.95. t XLVI, XLVII and XLVIII. L-pyroglutamyl-L-Histidine-hydrazide (10 mmol) is converted to azide by the method described in the general method, and combined with L-tryptophyl-L-serine methyl ester (11 mmol) obtained by hydrogenation of N-benzyloxycarbonyl derivative over 5 wt. 4 palladium on carbon in dimethylformamide at -10 C for 30 min and at C for 24 h. Triethylamine hydrochloride is filtered off, the filtrate is evaporated to dryness. The crude peptide is purified by column chromatography on silica gel using 10 as the eluting solvent vol .; methanol in chloroform, 20 vol. - methanol in chloroform and a mixture of chloroform: methanol: water 11: 8: 2. The product yield so pl. 142-145 C (with decomposition); fl, L 0.39; Rf, B 0.72; R,., C 0.5; . R, D 0.48; R, K 0.61. Xlix. A solution of L-pyroglutamyl-b-histidyl-b-tryptophyl-b-serine methyl ester (5.4 mmol) in 70 ml of dimethylformamide is treated with hydrazine hydrate (1p mmol) for 4 hours. The dimethylformamide is distilled off in vacuo, the residue triturated with ethanol, separated, washed with ethanol and ether, dried. Yield 88.2%, mp.184189C; Rf, A 0.18; Rj, B 0.55; C, 0.39; , D 0.27; R-, K 0.58. L. (A D-Trp). 4.87 g (23.6 mmol) of dicyclohexylcarbodiimide are added to a solution of 7.27 g (21.5 mmol) of N-benzyloxycarbonyl-O-tryptophan, 3.12 g (21.5 mmol) of leucine methyl ester and 5.8 g (43 mmol) of 1-hydroxybenzotriazole in 50 ml of dimethylformamide at. The reaction mixture is stirred overnight at room temperature and treated in the usual manner. After recrystallization from a mixture of ethyl acetate: petroleum ether (m “bp. 60-80 ° C), ipeptide derivative C 9.55 g) is obtained, in which traces of impurities are detected using thin-layer chromatography. The product was purified by GSTO silica gel column chromatography g /, using chloroform and 5 vol. Methanol in chloroform as elution solvent. The product yield 15 3,10 g (), so pl. 151-1530С; R, And O. Rf, B 0.80; Rn, C 0.86; Rp, D 0.78; R, E 0.61; Rf, F 0.68; Rj, H 0.73; R, P 0.55; Rf, Q 0.73. LI. (A D-Trp). Catalytic conversion in 80 vol.2; aqueous dimethyl formamide over 5% by weight palladium on carbon &amp; for 5 Cho LI I. (A D-Trp). Solution P, 69 g (20 mmol) of N-benzyloxycarbonyl-O-benzyl-L-tyrosine-2, 4 ester, trichlorophenyl, 6.28 g ((19 mmol of 0-tryptophyl-1-leucine ester in 100 ml of dimethylformamide stirring at room temperature for 60 hours. The reaction mixture is worked up in the usual way, and the residue is recrystallized from ethyl acetate: polyethyl ether (bp 60-80 C) to obtain a tripeptide derivative with an output of g (62.5%) - ton. Pl.165-166 C; R. g, A 0.78; Rr, B 0.73; Ro, C 0, Rr, D 0.80; R |, H 0.62; Rf, F 0.70; R, H 0.76; R, P 0.58; R, Q 0.68. LI I I. (A D-Trp) .7.26 r (10.1 mmol) of the methyl ester solution of M-benzyl xycarboiyl-0-benzyl-1-tyrosyl-O-tryptophyl-b-leucine in a mixture of 200 ml of methanol and 50 ml of dimethylformamide is treated with hydrazine hydrate (100 mmol) at room temperature. After 2k hours, the solution is concentrated (approximately 30 ml) and added 500 ml of water are added, the tripeptide hydrazide is separated, washed with water, a mixture of methanol: ether 1: A and ether and dried to give 6.86 (9.6%) of product with m.p. 200-202 0; R., A 0.90; R, B 0.95; Rf, C 0.90; R, D 0, RI, Q 0.59. LIV and LV. (. Trp). Under stirring and cooling () a solution of 1.97 g (2.75 mmol) of N-benzyloxycarbonyl-0-benzyl-1-tyrosyl-0-trypto fil-1-leucine hydrazide in 10 ml of dimethyl formamide is treated with 1.83 ml (P mmol ) 6.02 M solution of hydrogen chloride in dioxane, and then 0.33 ml (2.89 mmol) of tert.-butyl nitrite. After 2 minutes, a pre-cooled (-20c) solution of 1.02 (2.5 mmol) of N-nitro-L-arginyl-L-propyl-azaglycine-amide hydrochloride and 1.89 g (13.5 mmol), triethylamine in 10 ml of dimethylformamide and the resulting reaction mixture is stirred at. It is treated with the usual Cl method, the residue obtained (167 g) is placed in a column of silica gel (230 g) and the product is eluted with chloroform and 5 vol / methanol 3 chloroform. Yield 0.91 g (3.4%); m.p. 139-1 CC with decomposition); RJ, A 0.67; R {, B 0.72; RO, C 0.58; R, O 0.62; Rp, H 0, Rj, K 0.95. Lvi (A 0: Tug (Me)). To a solution cooled to О С 3.17 g (9.64 mmol ZD-Tyr (Me) -OH, 1.92 g (10.6 mmol) Leu-OMe, HC1, 2.6 g, (19.2 mmol) of 1-hydroxybenzotriazole and 1.6 ml (11 mmol) of triethylamine are added 2.29 g (11.1 mmol) of N, M-dicyclohexylcarbodiimide in 30 ml of dimethylformamide. overnight at c and treated in the usual manner. After recrystallization from hot cyclohexane, a protected dipeptide derivative is obtained. The yield is 1.41 g (95.2%); R, D 0.83; Rr, E 0, b9; Rr :, P 0.72; Rr, -Q 0.76G LVI I. (A 07Gog (Me)). Catalytic reduction over 5 weight, palladium on coal in cm Xi methanol: dimethylformamide: water 8: 1: 1, containing 1.2 equivalents of hydrogen chloride, for 3 hours. LVIII. (A 0-Tug (Me)). Solution (Bzl) -OCp (8.2 mmol). 0-Tug (Me) - Leu-OMe, HCl (b, 2 mmol) and triethylamine (8.2 mmol) in 60 ml of dimethylformamide is stirred at room temperature overnight, the reaction mixture is then treated in the usual way. The product is filtered, washed ether and dry. Yield 81.2%; m.p. 191-192 ° C; RJ, O 0.85; RI: 0.73; R, F 0.72; Rj, Q 0.78. LI X. ((Me)). Hydrazine hydrate (12.9 mmol) is added to a solution of 4.59 g (6.4 mmol) of Z-Tyr (Bz1) -0-Tug (Me) -Leu-Me in 25 ml of dimethylformamide and 50 ml of methanol and the reaction mixture left overnight at room temperature. The methanol is distilled off in vacuo, the product is precipitated with water, collected, washed with water and dried, to obtain the product with so pl. 212-213 0; Rr, E 0.49; Ri, F 0.66; Rj, H 0.69; Rr. Q 0.70. LX and LXIo (A D-Tyr (Me)). 3.54 g (iJ, 0 mmol) of the hydrazide obtained in the LIX stage are dissolved in 10 ml of dimethylformamide and cooled with stirring until the mixture is added to 173. "Ml (20. mmol) of 5.92 M HCl in dioxane, then 0.6 ml (5.25 mmol of tert-butyl nitrite. After 2 min, a pre-cooled solution of 2.0 g (5 MMO / fb) H -Arg (N) -Pgo-AzGly-NH HCl and 3.55 ml (25 mmol) of triethylamine in 10 ml of dimethylformamide; stirring is continued overnight. The reaction mixture is worked up in the usual way, and the resulting crude product is purified on a chromatographic column with silica gel, isp Chloroform, a 5 pDa mixture of methanol in chloroform and 10 pOD of methanol in chloroform are used as an eluting solvent. The yield is 3.72 g (70.9%); R, A 0.64; R, B 0.72; R , C 0.55; Rr, D 0.66; Rr, F p, AO; R., H 0.52., LXII. (A D-Ser (Bu)). Similar to stage LVI. The resulting product is recrystallized from aqueous Methanol Yield 90, mp. 107108C; RP, D 0.80; R, E 0.68; Rr, F 0.73; Rr, H 0.72; Ro, P 0.72; R., Q 0.7t. . LX1II „(A D-Ser (Bu)). Catalytic reduction over 5 wt. Pallas on carbon in a mixture of dimethylformamide: methanol 8: 2 for 5 hours, LXIV. (. Ser (But)), Rastor 19.17 g (32.7 mmol) Z-Tyr (Bzl) -OCp and H-Ser () -Leu-OMe (32.7 mmol) in 100 ml of dimethylpopamide is left at room temperature for 72 hours. As a result of the usual treatment of the solution, a solid is obtained, which is washed with ether and dried. Out 17.6 g 79,); m.p. 135-137 ° C; R, D 0.80; R, F 0.77; R- {, Q 0.81. Lxv (A D-Ser ()). Similar to the LIX stage. Recrystallization from aqueous methanol. Yield 56.2% / m.p. 13 -136 ° C; Rr, O 0.66; R, H 0, Rj, Q 0, LXVI and LXVII. (A D-Ser (Bu)). Stage LV and LXI are similar. The product obtained is purified by chromatography on a column of silica gel using chloroform and 5-n. Methanol in chloroform as elution solvent. Exit 38, m.p. Rj, A 0, HT; R, B 0.71; R, C 0.55; R, O 0.65; R, F 0, R, H 0.43; R, Q, 0.16. LXVII I. (A D-Tyr (Me)). 5.13 g (24.9 mmol of dicyclohexylcarbodiimide) is added to a cooled (and stirred solution of Z-0-Thug (Me) -OH (22.6 mmol), 5.98 g (24.9 mmol) of H-Me-Leu -OMe, HBg, 3.5 ml (24.9 mmol) of triethylamine and 6.12 g (45.2 mmol) of 1-hydroxybenzotriazole in 50 ml of dimethylformamide and stirring is continued overnight at. The reaction mixture is worked up in the usual way and the resulting product purified by silica gel column chromatography using chloroform for elution. Yield 55.2, oil; R, O 0.83; Rf, E 0.78; R, H 0.79; R, P 0.80; Rr, Q 0.79. LXIX. (A D-Tyr (Me)). Catalytic Reduction Over 5 V SD with palladium on carbon in methanol: water 8: 2 containing the equivalent of hydrogen chloride for 6 hours. LXX. (A D-Tyr (Me)). Similar to stage LVI II .. The product is purified by silica gel column chromatography. elution of ether. LXXI. (A D-Tyr (Me)). A solution of 4.85 g (6.69 mmol) of Z-Tyr (Bzl) -D-Tyr (Me) MeLeu-OMe and hydrazine hydrate. (120, 7 mmol) in 150 ml of methanol is kept overnight at room temperature. The hydrazide is precipitated by adding water, filtered and recrystallized from methanol: water. Yield 91.1%; m.p. 129-131 C; Rn, D 0.79; R, E 0.60; Rj, F 0.68; Rr, H 0.73; Rf, Q 0.77. LXXI I and LXXII I. Similar to stages LX and LXI. I Recrystallize from methanol: simple ether; yield 23.8%; m.p. 152-15 ° C; Ri. A 0.67; R, B 0.68; R, C, 0.58; Rf, D 0.59; R, H 0.50; R, K 0.94; Rf, Q 0,35la
    aXI
    t you
    (ABOUT
    21
    权利要求:
    Claims (1)
    [1]
    1. Schröder E. and Lyubka K. Peptides M., Mir 9b7, Part 1, p.
    and
    His
    Trp
    类似技术:
    公开号 | 公开日 | 专利标题
    SU910116A3|1982-02-28|Process for preparing polypeptides or their salts
    CA1156221A|1983-11-01|Processes for the preparation of new biologicallyactive peptides
    TWI515201B|2016-01-01|Process for the manufacture of degarelix and its intermediates
    DE CASTIGLIONE et al.1981|Synthesis of dermorphins, a new class of opiate‐like peptides
    US5977302A|1999-11-02|Liquid phase process for the preparation of GnRH peptides
    US3997516A|1976-12-14|Method for protecting guanidino group and restoring the same
    US4124703A|1978-11-07|Luliberin analogs
    US4491541A|1985-01-01|Peptides
    US4301066A|1981-11-17|Preparation of |-LH-RH via the heptapeptide H-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2
    EP0232435A2|1987-08-19|Serum thymic factor peptide analogs and a process for the preparation thereof
    GB2185025A|1987-07-08|Gonadoliberin derivatives containing an aromatic aminocarboxylic acid in the 6-position, pharmaceutical and veterinary compositions containing them and process for preparing same
    US3850904A|1974-11-26|Psychopharmacologically active d-glu or d-his containing peptides
    US3953415A|1976-04-27|Process for the preparation of biologically active polypeptides containing aspartyl group
    Van Nispen et al.1977|INVESTIGATION OF THE ROLE OF TRYPTOPHAN IN α‐MSH*: Replacement by L‐Pentamethylphenylalanine and L‐Phenylalanine
    Dutta et al.1979|Polypeptides. Part 15. Synthesis and biological activity of α-aza-analogues of luliberin modified in positions 6 and 10
    HU187503B|1986-01-28|Process for preparing gonadoliberine derivatives containing beta-aspartyl group
    RU2086561C1|1997-08-10|Method for production of nonapeptide ethyl amide
    Stewart1967|Peptide syntheses with the 2, 4, 6-trimethylbenzyl esters of L-asparagine and L-glutamine
    CA1131217A|1982-09-07|Psycho-pharmacological peptides
    Rzeszotarska et al.1984|Synthesis of Gonadoliberin, a gonadotropin releasing hormone
    US3767639A|1973-10-23|Process for the preparation of secretin
    Inouye et al.1976|Synthesis of Corticotropin Peptides. XIII. The Synthesis of a Hexacosapeptide and a Heptacosapeptide Corresponding to the First Twenty-six and Twenty-seven Amino Acid Residues of Corticotropin |
    Galpin et al.1979|Peptides-XXXIV: Synthesis of the 1–16 fragment of a lysozyme analogue
    CN111233980A|2020-06-05|Method for synthesizing goserelin by fragment method
    KR840000054B1|1984-01-31|Process for the preparation of thymosin
    同族专利:
    公开号 | 公开日
    DK207977A|1977-11-12|
    DK149596B|1986-08-04|
    ZA772433B|1978-03-29|
    SE437993B|1985-03-25|
    DE2720245C2|1986-09-25|
    NL970002I1|1997-03-03|
    NL7705130A|1977-11-15|
    YU40672B|1986-04-30|
    CH627151A5|1981-12-31|
    PL108860B1|1980-05-31|
    NL970002I2|1997-05-01|
    ATA217979A|1981-06-15|
    IL52014D0|1977-07-31|
    NL191793C|1996-08-02|
    FR2351092B1|1980-02-22|
    NO149586B|1984-02-06|
    ES458691A1|1978-08-16|
    FI64139C|1983-10-10|
    US4100274A|1978-07-11|
    ATA335877A|1985-05-15|
    DE2720245A1|1977-11-24|
    AU2468177A|1978-11-02|
    CS199673B2|1980-07-31|
    BG60740B2|1996-01-31|
    NO149586C|1984-05-16|
    DD136738A5|1979-07-25|
    CH629475A5|1982-04-30|
    GB1524747A|1978-09-13|
    AT379400B|1985-12-27|
    JPS52136172A|1977-11-14|
    SE8007763L|1980-11-05|
    YU117277A|1983-02-28|
    NL191793B|1996-04-01|
    DK149596C|1987-01-05|
    AU508025B2|1980-03-06|
    SE7705432L|1977-11-12|
    CA1101844A|1981-05-26|
    AT365562B|1982-01-25|
    PL197889A1|1978-02-13|
    NZ183931A|1979-03-16|
    JPS6113480B2|1986-04-14|
    PL104362B1|1979-08-31|
    NO771644L|1977-11-14|
    HU179990B|1983-01-28|
    IE44426B1|1981-11-18|
    SE437837B|1985-03-18|
    FR2351092A1|1977-12-09|
    BE854467A|1977-11-10|
    NO147304C|1983-03-16|
    FI771480A|1977-11-12|
    NO147304B|1982-12-06|
    IL52014A|1979-11-30|
    FI64139B|1983-06-30|
    IE44426L|1977-11-11|
    NO822984L|1977-11-14|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US4005063A|1973-10-11|1977-01-25|Abbott Laboratories|[Des-gly]10 -GnRH nonapeptide anide analogs in position 6 having ovulation-inducing activity|
    US3914412A|1973-10-11|1975-10-21|Abbott Lab|{8 Des{13 Gly{9 {0 10 -Gn{13 RH nonapeptide amide analogs in position 6 having ovulation-inducing activity|
    US3901872A|1974-03-13|1975-08-26|American Home Prod|P-glu-his-trp-ser-tyr-d-pgl-leu-arg-pro-gly-nh' 2 'and intermediates|
    JPS50142563A|1974-04-26|1975-11-17|
    US3896104A|1974-05-22|1975-07-22|American Home Prod|P-glu-his-trp-ser-tyr-d-lys-leu-arg-pro-gly-nh' 2 'and intermediates|
    DE2438350C3|1974-08-09|1979-06-13|Hoechst Ag, 6000 Frankfurt|Peptides with a strong LH-RH / FSH-RH action, process for their production and pharmaceutical preparations containing them|
    US3971737A|1975-03-24|1976-07-27|American Home Products Corporation|[2-Methyl-Ala6 ]LRH|
    US4010125A|1975-06-12|1977-03-01|Schally Andrew Victor|[D-Trp6 ]-LH-RH and intermediates therefor|
    US4018726A|1975-06-12|1977-04-19|Andrew Victor Schally|[D-Phe6 ]-LH-RH and intermediates therefor|
    US3992530A|1975-12-08|1976-11-16|American Home Products Corporation|[D-2-gly]6 -des-gly10 -lrh nonapeptide amides|
    US4024121A|1976-01-27|1977-05-17|Schally Andrew Victor|-Glu-His-Trp-D-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHR and intermediates|US4234571A|1979-06-11|1980-11-18|SyntexInc.|Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone|
    DE3411224A1|1984-03-27|1985-10-10|Hoechst Ag, 6230 Frankfurt|METHOD FOR THE RACEMATAR PRODUCTION OF INTERMEDIATE PEPTIDE PRODUCTS OF THE GONADORELIN AND GONADORELINANALOGA SYNTHESIS AND NEW INTERMEDIATE PRODUCTS IN THIS METHOD|
    US4760053A|1984-08-02|1988-07-26|Fernand Labrie|Combination therapy for selected sex steroid dependent cancers|
    US4666885A|1985-02-08|1987-05-19|Fernand Labrie|Combination therapy for treatment of female breast cancer|
    US4705778A|1985-10-22|1987-11-10|Sri International|Orally active LHRH analogs|
    JPH0284272U|1988-12-20|1990-06-29|
    JP2672677B2|1989-02-09|1997-11-05|タツプ・フアーマシユーテイカルズ・インコーポレイテツド|LHRH homolog|
    US5372996A|1989-03-10|1994-12-13|Endorecherche, Inc.|Method of treatment of androgen-related diseases|
    DE69022722T2|1989-03-10|1996-05-02|Endorecherche Inc|COMBINATION THERAPY FOR TREATING ESTROGEN SENSITIVE DISEASES.|
    ES2121570T3|1989-07-07|1998-12-01|Endorecherche Inc|ANDROGEN DERIVATIVES FOR USE IN THE INHIBITION OF THE ACTIVITY OF SEXUAL STEROIDS.|
    HUT60139A|1989-07-07|1992-08-28|Endorecherche Inc|Process for producing pharmaceutical composition suitable for treating prostate cancer connected with androgen|
    GB9112859D0|1991-06-14|1991-07-31|Ici Plc|Peptide process|
    CA2136304A1|1992-05-21|1993-11-25|Fernand Labrie|Inhibitors of testosterone 5.alpha.-reductase activity|
    US6413536B1|1995-06-07|2002-07-02|Southern Biosystems, Inc.|High viscosity liquid controlled delivery system and medical or surgical device|
    US7833543B2|1995-06-07|2010-11-16|Durect Corporation|High viscosity liquid controlled delivery system and medical or surgical device|
    CA2192782C|1995-12-15|2008-10-14|Nobuyuki Takechi|Production of microspheres|
    CA2192773C|1995-12-15|2008-09-23|Hiroaki Okada|Production of sustained-release preparation for injection|
    US6448031B1|1996-06-13|2002-09-10|Itoham Foods Inc.|Process for producing LH-RH derivatives|
    US6051558A|1997-05-28|2000-04-18|Southern Biosystems, Inc.|Compositions suitable for controlled release of the hormone GnRH and its analogs|
    US20060025328A1|1997-05-28|2006-02-02|Burns Patrick J|Compositions suitable for controlled release of the hormone GnRH and its analogs|
    US6242421B1|1997-11-06|2001-06-05|Richard Lloyd Bowen|Methods for preventing and treating Alzheimer's disease|
    US6858598B1|1998-12-23|2005-02-22|G. D. Searle & Co.|Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia|
    US6833373B1|1998-12-23|2004-12-21|G.D. Searle & Co.|Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia|
    US20040259803A1|1999-04-15|2004-12-23|Monash University|Disease prevention by reactivation of the thymus|
    US20040241842A1|1999-04-15|2004-12-02|Monash University|Stimulation of thymus for vaccination development|
    US20040265285A1|1999-04-15|2004-12-30|Monash University|Normalization of defective T cell responsiveness through manipulation of thymic regeneration|
    US20050020524A1|1999-04-15|2005-01-27|Monash University|Hematopoietic stem cell gene therapy|
    US20070274946A1|1999-04-15|2007-11-29|Norwood Immunoloty, Ltd.|Tolerance to Graft Prior to Thymic Reactivation|
    US20040258672A1|1999-04-15|2004-12-23|Monash University|Graft acceptance through manipulation of thymic regeneration|
    ES2154590B1|1999-05-20|2001-11-01|Lipotec Sa|SOLID PHASE SYNTHESIS PROCEDURE|
    AR023940A1|2000-05-03|2002-09-04|Eriochem Sa|PROCEDURE FOR THE PRODUCTION OF PROLONGED WATERPROOF PEPTIDE MICROCAPSULES IN WATER|
    DE10032256C2|2000-07-03|2003-06-05|Infineon Technologies Ag|Chip ID register configuration|
    US20060287282A1|2001-06-25|2006-12-21|Steiner Mitchell S|Compositions comprising a SARM ad GnRH agonist or a GnRH antagonist, and methods of use thereof|
    AUPR074500A0|2000-10-13|2000-11-09|Monash University|Treatment of t cell disorders|
    US20060088512A1|2001-10-15|2006-04-27|Monash University|Treatment of T cell disorders|
    LT3342411T|2001-02-19|2019-09-25|Novartis Pharma Ag|Rapamycin derivative for treating pancreas cancer|
    KR20080091866A|2001-05-16|2008-10-14|노파르티스 아게|Combination comprising n-{5-[4--benzoylamido]-2-methylphenyl}-4--2-pyrimidine-amine and a chemotherapeutic agent|
    US7812044B2|2001-11-13|2010-10-12|Takeda Pharmaceutical Company Limited|Anticancer agents|
    GB0128510D0|2001-11-28|2002-01-23|Novartis Ag|Organic compounds|
    US20030144203A1|2001-12-19|2003-07-31|Voyager Pharmaceutical Corporation|Methods for slowing senescence and treating and preventing diseases associated with senescence|
    GB0206215D0|2002-03-15|2002-05-01|Novartis Ag|Organic compounds|
    SI1505959T1|2002-05-16|2009-04-30|Novartis Ag|Use of edg receptor binding agents in cancer|
    US20040001889A1|2002-06-25|2004-01-01|Guohua Chen|Short duration depot formulations|
    US8133507B2|2002-12-13|2012-03-13|Durect Corporation|Oral drug delivery system|
    US20080279812A1|2003-12-05|2008-11-13|Norwood Immunology, Ltd.|Disease Prevention and Vaccination Prior to Thymic Reactivation|
    KR101204247B1|2003-07-22|2012-11-22|아스텍스 테라퓨틱스 리미티드|3,4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases cdk and glycogen synthase kinase-3 gsk-3 modulators|
    GB0320806D0|2003-09-05|2003-10-08|Astrazeneca Ab|Therapeutic treatment|
    KR20080083220A|2004-04-07|2008-09-16|노파르티스 아게|Inhibitors of iap|
    TW200607816A|2004-06-25|2006-03-01|Takeda Pharmaceuticals Co|Metastin derivatives and use thereof|
    ES2602273T3|2004-09-17|2017-02-20|Durect Corporation|Prolonged local anesthetic composition containing Saib|
    GB0425854D0|2004-11-25|2004-12-29|Astrazeneca Ab|Therapeutic treatment|
    KR101346886B1|2005-01-21|2014-01-02|아스텍스 테라퓨틱스 리미티드|Pharmaceutical compounds|
    US8404718B2|2005-01-21|2013-03-26|Astex Therapeutics Limited|Combinations of pyrazole kinase inhibitors|
    AR054425A1|2005-01-21|2007-06-27|Astex Therapeutics Ltd|PIPERIDIN ADDITION SALTS 4-IL-ACID AMID 4-1H-PIRAZOL-3-CARBOXILICO.|
    DE602006011099D1|2005-05-03|2010-01-28|Novetide Ltd|PROCESS FOR THE PREPARATION OF PEPTIDE DERIVATIVES|
    GB0510390D0|2005-05-20|2005-06-29|Novartis Ag|Organic compounds|
    GB0512324D0|2005-06-16|2005-07-27|Novartis Ag|Organic compounds|
    US20070027105A1|2005-07-26|2007-02-01|Alza Corporation|Peroxide removal from drug delivery vehicle|
    GT200600430A|2005-09-27|2007-05-21|CARBOXYAMINE COMPOUNDS AND SAME USE METHODS|
    GB0605120D0|2006-03-14|2006-04-26|Novartis Ag|Organic Compounds|
    MX2008014292A|2006-05-09|2008-11-18|Novartis Ag|Combination comprising an iron chelator and an anti-neoplastic agent and use thereof.|
    EP2081933B1|2006-09-29|2011-03-23|Novartis AG|Pyrazolopyrimidines as pi3k lipid kinase inhibitors|
    US8883790B2|2006-10-12|2014-11-11|Astex Therapeutics Limited|Pharmaceutical combinations|
    WO2008044041A1|2006-10-12|2008-04-17|Astex Therapeutics Limited|Pharmaceutical combinations|
    DK2117521T3|2006-11-03|2012-09-03|Durect Corp|TRANSDERMAL ADMINISTRATION SYSTEMS INCLUDING BUPIVACAIN|
    EP2120900A2|2007-02-15|2009-11-25|Novartis AG|Combination of lbh589 with other therapeutic agents for treating cancer|
    WO2009088414A2|2007-12-06|2009-07-16|Durect Corporation|Oral pharmaceutical dosage forms|
    BRPI0908603A2|2008-03-24|2020-08-18|Novartis Ag|matrix metalloprotease inhibitors based on arylsulfonamide.|
    CA2719477C|2008-03-26|2016-11-08|Novartis Ag|Hydroxamate-based inhibitors of deacetylases b|
    US20100260844A1|2008-11-03|2010-10-14|Scicinski Jan J|Oral pharmaceutical dosage forms|
    KR101749353B1|2008-11-28|2017-06-20|노파르티스 아게|Pharmaceutical combination comprising a hsp90 inhibitor and a mtor inhibitor|
    WO2010083617A1|2009-01-21|2010-07-29|Oncalis Ag|Pyrazolopyrimidines as protein kinase inhibitors|
    JP2012516345A|2009-01-29|2012-07-19|ノバルティスアーゲー|Substituted benzimidazoles for astrocytoma treatment|
    CA2765983C|2009-06-26|2017-11-14|Novartis Ag|1,3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17|
    US8389526B2|2009-08-07|2013-03-05|Novartis Ag|3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives|
    BR112012003262A8|2009-08-12|2016-05-17|Novartis Ag|Heterocyclic Hydrazone Compounds and Their Uses to Treat Cancer and Inflammation|
    MX2012002179A|2009-08-20|2012-03-16|Novartis Ag|Heterocyclic oxime compounds.|
    EA201200321A1|2009-08-26|2012-09-28|Новартис Аг|TETRA-SUBSTITUTED HETEROARRYL COMPOUNDS AND THEIR USE AS MDM2 AND / OR MDM4 MODULATORS|
    CN102596963A|2009-09-10|2012-07-18|诺瓦提斯公司|Ether derivatives of bicyclic heteroaryls|
    MX2012005293A|2009-11-04|2012-06-19|Novartis Ag|Heterocyclic sulfonamide derivatives useful as mek inhibitors.|
    US20120289501A1|2009-11-25|2012-11-15|Novartis Ag|Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls|
    PE20121384A1|2009-12-08|2012-10-13|Novartis Ag|HETEROCYCLIC SULFONAMIDE DERIVATIVES|
    US8440693B2|2009-12-22|2013-05-14|Novartis Ag|Substituted isoquinolinones and quinazolinones|
    CN102947275A|2010-06-17|2013-02-27|诺瓦提斯公司|Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives|
    CN102947274A|2010-06-17|2013-02-27|诺瓦提斯公司|Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives|
    US8653092B2|2010-07-06|2014-02-18|Novartis Ag|Tetrahydro-pyrido-pyrimidine derivatives|
    EP2627648A1|2010-09-16|2013-08-21|Novartis AG|17aHYDROXYLASE/C17,20-LYASE INHIBITORS|
    KR101561750B1|2010-11-19|2015-10-19|노파르티스 아게|Crystalline form of an inhibitor of mdm2/4 and p53 interaction|
    EP2673277A1|2011-02-10|2013-12-18|Novartis AG|[1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase|
    JP2014507465A|2011-03-08|2014-03-27|ノバルティスアーゲー|Fluorophenyl bicyclic heteroaryl compounds|
    BR112013027395A2|2011-04-28|2017-01-17|Novartis Ag|17alphahydroxylase / c17,20-lyase inhibitors|
    EP2709991B1|2011-05-16|2020-09-02|Genzyme Corporation|Use of cxcr4 antagonists for treating WHIM syndrome, myelokathexis, neutropenia and lymphocytopenia|
    IN2014DN00123A|2011-06-09|2015-05-22|Novartis Ag|
    US8859535B2|2011-06-20|2014-10-14|Novartis Ag|Hydroxy substituted isoquinolinone derivatives|
    WO2012175487A1|2011-06-20|2012-12-27|Novartis Ag|Cyclohexyl isoquinolinone compounds|
    AU2012277391A1|2011-06-27|2013-12-19|Novartis Ag|Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives|
    UY34329A|2011-09-15|2013-04-30|Novartis Ag|TRIAZOLOPIRIDINE COMPOUNDS|
    JP5992054B2|2011-11-29|2016-09-14|ノバルティス アーゲー|Pyrazolopyrrolidine compound|
    AP4055A|2011-12-22|2017-03-07|Novartis Ag|Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives|
    US20150148377A1|2011-12-22|2015-05-28|Novartis Ag|Quinoline Derivatives|
    CN104136428A|2011-12-23|2014-11-05|诺华股份有限公司|Compounds for inhibiting the interaction of bcl2 with binding partners|
    EP2794592A1|2011-12-23|2014-10-29|Novartis AG|Compounds for inhibiting the interaction of bcl2 with binding partners|
    US20140357666A1|2011-12-23|2014-12-04|Novartis Ag|Compounds for inhibiting the interaction of bcl2 with binding partners|
    BR112014015274A8|2011-12-23|2017-06-13|Novartis Ag|compounds and compositions for inhibiting bcl2 interaction with binding partners|
    EP2794591A1|2011-12-23|2014-10-29|Novartis AG|Compounds for inhibiting the interaction of bcl2 with binding partners|
    UY34591A|2012-01-26|2013-09-02|Novartis Ag|IMIDAZOPIRROLIDINONA COMPOUNDS|
    US20130310387A1|2012-05-16|2013-11-21|Novartis Ag|Monocyclic Heteroaryl Cycloalkyldiamine Derivatives|
    US9365576B2|2012-05-24|2016-06-14|Novartis Ag|Pyrrolopyrrolidinone compounds|
    EP2861256B1|2012-06-15|2019-10-23|The Brigham and Women's Hospital, Inc.|Compositions for treating cancer and methods for making the same|
    MX2015002006A|2012-08-13|2015-06-02|Novartis Ag|Bicyclic heteroaryl cycloalkyldiamine derivatives as inhibitors of spleen tyrosine kinases .|
    LT2903968T|2012-10-02|2017-02-27|Gilead Sciences, Inc.|Inhibitors of histone demethylases|
    TW201422625A|2012-11-26|2014-06-16|Novartis Ag|Solid form of dihydro-pyrido-oxazine derivative|
    WO2014115080A1|2013-01-22|2014-07-31|Novartis Ag|Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction|
    US9403827B2|2013-01-22|2016-08-02|Novartis Ag|Substituted purinone compounds|
    WO2014128612A1|2013-02-20|2014-08-28|Novartis Ag|Quinazolin-4-one derivatives|
    EA030451B1|2013-02-27|2018-08-31|Эпитерапьютикс Апс|Inhibitors of histone demethylases|
    US9572885B2|2013-03-15|2017-02-21|Durect Corporation|Compositions with a rheological modifier to reduce dissolution variability|
    US20150018376A1|2013-05-17|2015-01-15|Novartis Ag|Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof|
    UY35675A|2013-07-24|2015-02-27|Novartis Ag|SUBSTITUTED DERIVATIVES OF QUINAZOLIN-4-ONA|
    US9227969B2|2013-08-14|2016-01-05|Novartis Ag|Compounds and compositions as inhibitors of MEK|
    WO2015022663A1|2013-08-14|2015-02-19|Novartis Ag|Compounds and compositions as inhibitors of mek|
    WO2015022664A1|2013-08-14|2015-02-19|Novartis Ag|Compounds and compositions as inhibitors of mek|
    EP3046563B1|2013-09-22|2019-05-29|Calitor Sciences, LLC|Substituted aminopyrimidine compounds as pi3-kinase inhibitors|
    AU2015207723A1|2014-01-15|2016-06-09|Novartis Ag|Pharmaceutical combinations|
    WO2015148868A1|2014-03-28|2015-10-01|Calitor Sciences, Llc|Substituted heteroaryl compounds and methods of use|
    WO2015153498A1|2014-03-31|2015-10-08|Epitherapeutics, Aps|Inhibitors of histone demethylases|
    WO2015153345A1|2014-04-03|2015-10-08|Invictus Oncology Pvt. Ltd.|Supramolecular combinatorial therapeutics|
    TW201625536A|2014-08-27|2016-07-16|艾比療法公司|Compounds and methods for inhibiting histone demethylases|
    JP2018527362A|2015-09-11|2018-09-20|サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ．|Substituted heteroaryl compounds and methods of use|
    EP3730483A4|2017-12-21|2021-07-28|Hefei Institutes of Physical Science, Chinese Academy of Sciences|Class of pyrimidine derivative kinase inhibitors|
    WO2021097256A1|2019-11-14|2021-05-20|Cohbar, Inc.|Cxcr4 antagonist peptides|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    GB19327/76A|GB1524747A|1976-05-11|1976-05-11|Polypeptide|
    [返回顶部]